Status:
COMPLETED
Dose Response of Inhaled Tacrolimus in Patients With Moderate Persistent Asthma
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma Europe B.V.
Conditions:
Asthma, Bronchial
Bronchial Asthma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.
Eligibility Criteria
Inclusion
- Diagnosis of asthma
- Patients treated with inhaled corticosteroid
- FEV1 (forced expiratory volume in 1 second)\>60% to 80%
Exclusion
- Respiratory infection within 2 weeks
- Asthma exacerbation within 90 days
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
370 Patients enrolled
Trial Details
Trial ID
NCT00189787
End Date
August 1 2005
Last Update
April 17 2008
Active Locations (49)
Enter a location and click search to find clinical trials sorted by distance.
1
Pleven, Bulgaria, 5800
2
Rousse, Bulgaria, 7000
3
Sofia, Bulgaria, 1431
4
Varna, Bulgaria, 9010